Relacorilant Shows Promise in Advanced Ovarian Cancer, Regulatory Filings Advance
New data reveals a potential breakthrough in the treatment of platinum-resistant ovarian cancer, as relacorilant, combined with nab-paclitaxel, demonstrates a progression-free survival (PFS) advantage in patients previously exposed to PARP inhibitors. Corcept Therapeutics is also actively pursuing regulatory approvals in both the US and Europe, marking a significant milestone for the novel therapy.
Understanding Platinum-Resistant Ovarian Cancer and the Role of Relacorilant
Ovarian cancer is often diagnosed at a late stage, making treatment challenging. While initial treatment with platinum-based chemotherapy is often effective, many patients develop resistance, leading to disease progression. This platinum-resistant ovarian cancer represents a significant unmet medical need.
Relacorilant is a selective glucocorticoid receptor (GR) modulator. Unlike traditional corticosteroids, relacorilant aims to block the GR, which is often overexpressed in cancer cells and contributes to treatment resistance. By selectively modulating the GR, relacorilant seeks to restore sensitivity to chemotherapy and improve patient outcomes.
Recent findings presented at the European Society for Medical Oncology (ESMO) 2025 showcased relacorilant’s benefit when combined with nab-paclitaxel in patients with platinum-resistant ovarian cancer who had previously undergone PARP inhibitor treatment. This combination therapy demonstrated a statistically significant improvement in progression-free survival (PFS), a key measure of treatment efficacy. OncLive provides further details on these results.
Corcept Therapeutics has filed a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for relacorilant in the treatment of platinum-resistant ovarian cancer. Nasdaq reports on this significant regulatory step.
Beyond ovarian cancer, Corcept is also evaluating relacorilant in other solid tumors. The company is simultaneously pursuing approvals for other compounds, including navepegritide and icotrokinra, highlighting a robust pipeline of innovative therapies. Citeline News & Insights details these broader development efforts.
Analysts are closely watching Corcept Therapeutics, particularly following the European regulatory filing. simplywall.st provides an assessment of the company’s valuation in light of these developments.
What impact will relacorilant have on the treatment landscape for platinum-resistant ovarian cancer? And how will Corcept’s broader pipeline influence its future growth?
Frequently Asked Questions About Relacorilant
What is relacorilant and how does it work in ovarian cancer?
Relacorilant is a selective glucocorticoid receptor (GR) modulator designed to block the GR, which is often overexpressed in cancer cells and contributes to treatment resistance. This aims to restore sensitivity to chemotherapy.
What were the key findings from the ESMO 2025 presentation on relacorilant?
The presentation demonstrated a statistically significant improvement in progression-free survival (PFS) when relacorilant was combined with nab-paclitaxel in patients with platinum-resistant ovarian cancer who had previously undergone PARP inhibitor treatment.
What is the current regulatory status of relacorilant?
Corcept Therapeutics has filed a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for relacorilant in platinum-resistant ovarian cancer.
What other therapies is Corcept Therapeutics developing?
Corcept is also developing navepegritide and icotrokinra, demonstrating a robust pipeline of innovative therapies beyond relacorilant.
How does relacorilant differ from traditional corticosteroids?
Unlike traditional corticosteroids, relacorilant is a selective GR modulator, aiming to block the GR rather than broadly activating it, potentially minimizing side effects and maximizing therapeutic benefit.
Discover more from Archyworldys
Subscribe to get the latest posts sent to your email.
